• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

previll@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Infectious Diseases
ORCID

0000-0003-0327-5942

Prof Peter Revill

Honorary (Professorial Fellow)
Department of Infectious Diseases

183 Scholarly works
20 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B
    DOI: 10.1093/infdis/jiaf569
  • 2026

    Journal article

    Overview of gene editing strategies against HBV
    DOI: 10.1016/j.antiviral.2026.106355
  • 2026

    Journal article

    Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
    DOI: 10.1093/cid/ciaf281
  • 2025

    Journal article

    Hepatitis B surface antigen is upregulated by HIV Tat in an HIV–hepatitis B virus co-infection model system
    DOI: 10.1128/spectrum.00809-25
  • 2022

    Research Grant

    Developing a Novel RNA Therapeutic for Chronic Hepatitis B
  • 2022

    Research grants (other domestic)

    Developing a Novel RNA Therapeutic for Chronic Hepatitis B
  • 2022

    Internal Research Grant

    Developing a Novel RNA Therapeutic for Chronic Hepatitis B
Peter Revill

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Availability of point-of-care HBV tests in resource-limited settings
    DOI: 10.1016/S2468-1253(24)00308-X
  • 2024

    Journal article

    CRISPR-Cas13b-mediated suppression of HBV replication and protein expression
    DOI: 10.1016/j.jhep.2024.05.025
  • 2024

    Conference Proceedings

    ANTI- HBS IMMUNE COMPLEX LEVELS: A NOVEL BIOMARKER OF HEPATITIS FLARE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B WHO STOP NUCLEOS( T) IDE ANALOGUE THERAPY
  • 2024

    Journal article

    High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
    DOI: 10.1111/liv.16029
  • 2024

    Conference Proceedings

    Anti-HBs immune complex levels: A novel biomarker of hepatitis flare in patients with HBeAg-negative chronic hepatitis B who stop nucleos(t)ide analogue therapy
  • 2024

    Journal article

    The impact of hepatitis B virus (HBV) splicing on HBV replication and disease progression
    DOI: 10.37349/edd.2024.00054

RECENT PROJECTS

  • 2023

    Research Grant

    Novel Monoclonal Antibodies to Treat Chronic Hepatitis B
  • 2023

    Research Grant

    Novel Monoclonal Antibodies to Treat Chronic Hepatitis B

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224